Scott N. Boyle - Feb 13, 2024 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Chief Business Officer
Signature
/s/ Jolie M. Siegel, Attorney-in-Fact
Stock symbol
CCCC
Transactions as of
Feb 13, 2024
Transactions value $
-$11,330
Form type
4
Date filed
2/15/2024, 05:03 PM
Previous filing
Sep 19, 2023
Next filing
Mar 8, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CCCC Common Stock Tax liability -$11.3K -1.74K -6.48% $6.53 25K Feb 13, 2024 Direct F1
transaction CCCC Common Stock Award $0 +27.3K +109.07% $0.00 52.3K Feb 14, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CCCC Stock Option (Right to Buy) Award $0 +123K $0.00 123K Feb 14, 2024 Common Stock 123K $7.31 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") and does not represent a sale by the Reporting Person.
F2 Represents RSUs. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2025.
F3 The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2024.